Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Stu
Authors
Marian Iwamoto (ORCID: https://orcid.org/0000-0002-8334-4815)
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Stu
Marian Iwamoto, Arinjita Bhattacharyya, Liliana Preoțescu, Randolph P. Matthews et al.
Journal
Clinical Infectious Diseases
Topics
HIV/AIDS drug development and treatment
article
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Stu
Marian Iwamoto, Arinjita Bhattacharyya, Liliana Preoțescu, Randolph P. Matthews, Mohammed Rassool, Graigory Garrett, Caroline Cilissen, Carlien Leyssens, Yash Kapoor, Tom Reynders, Johannes Lombaard, Gillian Gillespie, Ryan C. Vargo, Anca Streinu-Cercel, Jean‐François Denef, Russ P. Carstens, S Aubrey Stoch, Richard Kaplan, Xiaowei Zang, Adedayo Adedoyin
article en
Abstract
No abstract available for this paper.
Publication Tag
Clinical Infectious Diseases
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Desmond Tutu HIV Foundation (ZA), Carol Davila University of Medicine and Pharmacy (RO), Infectious Diseases Institute (UG), MSD (Belgium) (BE), Clinvet (ZA), Helen Joseph Hospital (ZA)